Clinical Trials Logo
  1. Home
  2. Scalp Psoriasis
  3. NCT01052467
  4. Details
NCT01052467 Clinical Trial

Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)

Scalp Psoriasis Clinical Trial

Official title:
Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01052467
Other study ID # Treatment with Xamiol® Gel
Secondary ID
Status Completed
Phase N/A
First received January 19, 2010
Last updated February 18, 2014
Start date January 2010
Est. completion date May 2010

Study information
Verified date September 2010
Source LEO Pharma
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Observational

Clinical Trial Summary

This non-interventional, prospective, non-controlled study of Xamiol® Gel, a fixed combination of calcipotriol and betamethason dipropionate, shall investigate in daily routine the efficacy, tolerability and changes in quality-of-life parameters in patients with scalp psoriasis

Recruitment information / eligibility
Status Completed
Enrollment 724
Est. completion date May 2010
Est. primary completion date May 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with scalp psoriasis if a treatment with Xamiol® gel is planned anyway

Exclusion Criteria:

- Contraindications of Xamiol® Gel listed in the German package insert

- Pretreatment with Xamiol® within the last 4 weeks

- Systemic treatment of psoriasis

- UV light therapy

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Intervention

Drug:
• Xamiol® Gel
Once daily application for about 4 weeks

Locations
Country Name City State
Germany University Clinical Schleswig-Holstein, Campus Kiel Kiel

Sponsors (1)
Lead Sponsor Collaborator
LEO Pharma

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary Physician's Global Assessment of scalp psoriasis After approximately 4 weeks No
Secondary Patient's Quality of Life After approximately 4 weeks No
See also
  Status Clinical Trial Phase
Completed NCT00400725 - Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis Phase 3
Completed NCT01195831 - Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis Phase 3
Completed NCT03880357 - To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis Phase 1
Completed NCT03331523 - To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis Phase 3
Completed NCT04801433 - Evaluate the Efficacy and Safety of Boroda Supramolecular Active Zinc in the Treatment of Scalp Psoriasis N/A
Completed NCT01120223 - Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis Phase 2
Completed NCT03897088 - Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis Phase 3
Completed NCT02932462 - Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis Phase 3
Completed NCT02933866 - Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis Phase 3
Completed NCT05872256 - A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis Phase 4
Active, not recruiting NCT05272150 - Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis Phase 3
Completed NCT02933502 - Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product Phase 2
Completed NCT04243486 - A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis Phase 2
Recruiting NCT02749656 - Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis Phase 3
Completed NCT02078297 - IL-17 Role in Variants of Psoriasis N/A
Completed NCT00438399 - Subject Preference for Scalp Psoriasis Treatment Phase 3
Completed NCT05028582 - Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) Phase 3
Completed NCT01914627 - Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis Phase 2
Not yet recruiting NCT01558310 - A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis Phase 4
Recruiting NCT05969223 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis Phase 4